(Q38069507)

28 August 2017

1 reference

title

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

Sheldon Russell

1

1 reference

28 August 2017

publication date

22 December 2012

1 reference

International Journal of Clinical Pharmacy

28 August 2017

published in

1 reference

28 August 2017

volume

35

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

159-172

1 reference

https://scigraph.springernature.com/pub.10.1007/s11096-012-9729-9

28 August 2017

exact match

0 references

cites work

Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

21 January 2018

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Medication taking and diabetes: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Incretin-based therapies: review of current clinical trial data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-012-9729-9

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

21 January 2018

1 reference

12 December 2020

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

12 December 2020

Managing the "geriatric syndrome" in patients with type 2 diabetes

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

10.1007/S11096-012-9729-9

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1000666344

0 references

1 reference